Fulcrum (FULC) is Allocating 95% of the Combined Company to Slate and PIPE Investors. Is the $270M Dividend Enough?

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) recently merged with Slate Medicines, transforming the publicly traded company into a migraine-focused biotechnology business. Slate Medicines contributed its drug assets, while new investors supplied $245 million. Legacy Fulcrum shareholders would own 5% of the combined company, while Slate Medicines would hold 55.9% and PIPE investors would own 39.1%, subject to adjustment.

In exchange for the merger, Fulcrum Therapeutics, Inc. (NASDAQ:FULC) expects to distribute an estimated $270 million cash dividend, which equates to approximately $3.54 per share, based on 76.2 million shares outstanding as of July 23. This dividend, combined with a $0.41 stub, amounts to roughly $3.95 in gross illustrative value, surpassing Monday's closing price of $3.84 by 11 cents.

The dividend's actual value will depend on several factors, including the closing net cash, share count, and other transaction adjustments.